Reply to: "The "cholesterol paradox" in patients with mastocytosis"
To the Editor,
We read with interest the Letter to the Editor “The “cholesterol paradox” in patients with mastocytosis” by Feminò and Feminò and we would like to thank the authors for their vision on our recently published data. In our paper, we have found a significantly higher prevalence of cardiovascular events in patients with systemic mastocytosis (SM), which is a disease characterized by the accumulation of mast cells in one or more organs, compared to matched control subjects. Remarkably, we observed significantly lower circulating total and LDL cholesterol levels in patients with SM compared to the controls. An interesting point has been raised by the authors with respect to that specific finding, and we would like to take the opportunity to address that here. [...]
|Persistent URL||dx.doi.org/10.1016/j.atherosclerosis.2019.02.018, hdl.handle.net/1765/116770|
Bot, I, Mulder, M.T, Indhirajanti, S, van Daele, P.L.A, & Roeters van Lennep, J.E. (2019). Reply to: "The "cholesterol paradox" in patients with mastocytosis". Atherosclerosis, 284, 262–263. doi:10.1016/j.atherosclerosis.2019.02.018